Morin Cancer Research Results

MOR, Morin: Click to Expand ⟱
Features:

Morin — 2′,3,4′,5,7-pentahydroxyflavone is a naturally occurring polyphenolic flavonol with antioxidant, anti-inflammatory, metabolic, neuroprotective, and antiproliferative activity. It is a small-molecule dietary flavonoid, commonly abbreviated MOR or MRN, and occurs in plants including Morus, Maclura, Artocarpus, and Psidium species. Morin is experimentally notable for pleiotropic inhibition of oncogenic STAT3, NF-κB, and PI3K/AKT signaling while producing context-dependent redox effects: it can increase ROS in cancer cells yet activate antioxidant defenses such as NRF2/HO-1 in non-malignant tissue. Its therapeutic development is strongly constrained by poor aqueous solubility, extensive intestinal first-pass metabolism, and extremely low oral bioavailability.

Primary mechanisms (ranked):

  1. STAT3 suppression through SHP1 induction and inhibition of upstream JAK/Src signaling, reducing survival, proliferation, angiogenesis, and therapy resistance.
  2. NF-κB suppression through inhibition of IKK/IκBα signaling, decreasing anti-apoptotic, proliferative, inflammatory, and invasive gene expression.
  3. PI3K/AKT survival signaling inhibition, contributing to apoptosis, cell-cycle arrest, suppression of invasion, and chemosensitization.
  4. Mitochondrial and death-receptor apoptosis through Bax/Bcl-2 modulation, mitochondrial membrane depolarization, cytochrome-c release, Fas activation, and caspase-8/9/3 activation.
  5. ROS elevation in several cancer models, contributing to mitochondrial dysfunction and apoptotic signaling; redox direction is cell- and dose-dependent.
  6. Suppression of aerobic glycolysis and the Warburg phenotype through reduced GLUT1/glucose uptake and cellular ATP availability in susceptible cancer models.
  7. Hippo pathway activation with MST1 activation and YAP nuclear exclusion, accompanied by suppression of Wnt/β-catenin signaling in some models.
  8. Suppression of EMT, invasion, and metastasis-associated signaling including MMP-9 and N-cadherin.
  9. Chemosensitization, including experimental enhancement of paclitaxel, doxorubicin, 5-fluorouracil, bortezomib, and thalidomide responses through overlapping STAT3, NF-κB, PI3K/AKT, FOXM1, and DNA-repair mechanisms.
  10. NRF2/HO-1 antioxidant signaling activation, principally a cytoprotective mechanism in normal or inflammatory tissue rather than a core anticancer mechanism.

Bioavailability / PK relevance: Oral exposure is a major limitation. Rat studies report absolute oral bioavailability of approximately 0.45%, with poor aqueous solubility, low intestinal permeability, and extensive intestinal first-pass metabolism contributing to low systemic exposure. Intraportal bioavailability is high, indicating that presystemic rather than systemic elimination is a dominant limitation. Lipid nanoparticles, niosomes, phospholipid complexes, and other delivery systems can increase exposure experimentally, but no clinically validated morin formulation has been established.

In-vitro vs systemic exposure relevance: Many anticancer experiments employ approximately 50–300 µM morin, with some reported IC50 values exceeding 100–200 µM. These concentrations are unlikely to be reproduced by conventional oral morin because of its approximately 0.45% oral bioavailability. Accordingly, direct extrapolation of high-concentration cell-culture cytotoxicity to oral human use is inappropriate. Lower-concentration pathway modulation and formulation-enhanced delivery may be more translationally relevant.

Clinical evidence status: Preclinical. Anticancer evidence consists primarily of cell-culture experiments and animal models, with no established human anticancer efficacy or approved therapeutic indication. Combination effects with chemotherapy remain experimental. Alzheimer’s/neuroprotective evidence is likewise preclinical, including cultured neurons and several transgenic or chemically induced animal models.

Morin Dietary Sources and Mulberry Preparations

Rank Food or Preparation Morin Content Measurement Basis Evidence Notes / Interpretation
1 White mulberry fruit, freeze-dried (Morus alba) 16 mg/100 g Freeze-dried fruit powder Quantified by HPLC Best documented mulberry fruit preparation for morin content. Equivalent to 4 mg per 25 g serving, assuming comparable composition. Not necessarily representative of commercial sun-dried products.
2 White mulberry leaves, dried (Morus alba) 1.69–13.87 mg/100 g Dry leaf weight Quantified by HPLC Morin varies substantially between cultivars. BR-2 contained 13.87 mg/100 g, while S-36 contained 1.69 mg/100 g. Values reflect laboratory extraction, not tea infusion yield.
3 Natural dried white mulberries (Morus alba) Not established Sun-dried or shade-dried whole fruit Indirect evidence Readily available as an unsweetened dried fruit. Morin is expected to be present, but commercial drying retention has not been quantified. Low-temperature and shade drying generally preserve phenolic compounds better than high-temperature drying.
4 White mulberry leaf extract (Morus alba) Not standardized Commercial aqueous or hydroalcoholic extract Morin identified and quantified in experimental extracts Potentially more concentrated than whole leaves, depending on extraction ratio, solvent, cultivar and purification. A 10:1 extract does not necessarily contain ten times the morin concentration. Standardized morin assays are uncommon.
5 Black mulberry fruit (Morus nigra) Not reliably quantified Fresh or dried fruit Extensive polyphenol research; morin-specific data limited Generally contains more total phenolics and anthocyanins than white mulberry. Higher total flavonoids do not establish higher morin content. Particularly useful as a source of anthocyanins.
6 Mulberry leaf tea (Morus alba) Not established per cup Hot-water infusion of dried leaves Leaf morin quantified; tea transfer not established Typical preparations use approximately 2–3 g dried leaves per cup. At the reported leaf concentrations, this corresponds to approximately 0.034–0.416 mg morin in the leaves before brewing. Actual transfer into tea is unknown and may be considerably lower.
7 Black mulberry leaves and leaf extracts (Morus nigra) Not established Dried leaves, infusions and extracts Phenolic composition studied Rich in quercetin and kaempferol derivatives and phenolic acids. No sufficiently reliable concentration is available to establish superiority over white mulberry for morin.
8 Mulberry fruit extract (Morus alba or Morus nigra) Not standardized Powdered or concentrated fruit extract Extract composition varies Often standardized for total polyphenols or anthocyanins rather than morin. Solvent selection and extraction methods strongly influence flavonol composition.
9 Fresh white mulberries (Morus alba) Not established Fresh fruit Indirect evidence from dried fruit Contains morin, but concentrations per 100 g fresh weight cannot be confidently assigned from the freeze-dried powder data without matched moisture and recovery measurements.
10 Strawberry fruit (Fragaria species) 10.1 mg/100 g dry phenolic extract Concentrated phenolic extract Quantified in extract Reported as 101 ± 68 µg/g extract. This concentration does not represent the edible fresh fruit and is not directly comparable to whole dried mulberries.
11 Guava (Psidium guajava) Not established Fruit and leaves Botanical occurrence reported Morin-related flavonoids occur in guava tissues, especially leaves. Reliable dietary morin concentrations in edible fruit are unavailable.
12 Apple peel and whole apple (Malus domestica) Not established Peel and flesh Limited detection evidence Apple peel contains substantially more flavonols than flesh, predominantly quercetin glycosides. There is insufficient evidence that apple peel is a meaningful concentrated morin source.

Ranking interpretation: The ranking combines morin-specific analytical evidence with practical dietary availability. It is not a quantitative ranking of actual morin intake. Products lacking a morin assay cannot be reliably compared against those with measured concentrations.

White versus black mulberry: White mulberry has better documented morin concentrations in fruit and leaves. Black mulberry is generally richer in total phenolics and anthocyanins, but its morin concentration remains insufficiently characterized.

Natural dried fruit: Unsweetened, low-temperature dried white mulberries are a practical source, but the reported 16 mg/100 g freeze-dried value should not be assumed for commercial naturally dried berries.

Tea versus extracts: Mulberry leaf tea contains water-extractable polyphenols, but morin yield per cup is not established. Commercial leaf extracts may offer more concentrated flavonoids, although most are not standardized for morin. Laboratory methanolic extraction results should not be treated as equivalent to drinking tea.

Clinical relevance: Dietary morin exposure is likely much lower than the concentrations used in many anticancer cell-culture experiments. No food-based morin dose has demonstrated clinical anticancer efficacy.

Morin Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 SHP1 JAK Src STAT3 signaling SHP1 ↑; JAK1/2 ↓; Src ↓; p-STAT3 ↓; STAT3 nuclear signaling ↓ ↔ (insufficient comparative evidence) R, G Oncogenic survival signaling suppression One of the strongest mechanistically defined morin targets. SHP1 knockdown attenuates STAT3 suppression, supporting a causal SHP1-dependent mechanism.
2 NF-κB survival and inflammatory signaling IKK ↓; IκBα degradation ↓; p65 nuclear translocation ↓; NF-κB transcription ↓ NF-κB ↓ (in inflammatory models) R, G Anti-survival and anti-inflammatory signaling Downstream effects include survivin ↓, Bcl-xL ↓, IAPs ↓, cyclin D1 ↓, COX-2 ↓, and MMP-9 ↓.
3 PI3K AKT survival signaling PI3K ↓; p-AKT ↓ ↔ (context-dependent) R, G Growth, survival, and invasion suppression AKT inhibition occurs in several cancer models and can occur at lower morin concentrations in malignant than corresponding normal oral cells.
4 Mitochondrial and death-receptor apoptosis Fas ↑; Bax ↑; Bcl-2 ↓; ΔΨm ↓; cytochrome c ↑; caspase-8/9/3 ↑ Apoptosis ↔ or ↓ in oxidative-injury models R, G Intrinsic and extrinsic apoptosis Both mitochondrial and Fas-associated death pathways have been demonstrated; magnitude is strongly concentration- and model-dependent.
5 Pro-oxidant ROS and mitochondrial stress ROS ↑ (model-dependent); ΔΨm ↓ ROS ↓; antioxidant defense ↑ P, R Context-selective redox stress Morin behaves as a redox modulator rather than a universal antioxidant. ROS elevation accompanies apoptosis in several cancer cell models.
6 Glycolysis and Warburg metabolism GLUT1 ↓; glucose uptake ↓; ATP ↓ ↔ R, G Energetic stress Demonstrated particularly in SW480 colorectal cancer cells; evidence is less broad than for STAT3, NF-κB, or AKT.
7 Hippo MST1 YAP and Wnt β-catenin signaling MST1 ↑; YAP nuclear localization ↓; β-catenin signaling ↓ Context-dependent R, G Growth signaling suppression and apoptosis Strong mechanistic evidence exists in selected hepatocellular models but should not yet be generalized across all cancers.
8 Cell-cycle control G2/M arrest ↑; CDK1 activity ↓; cyclin B1 ↓; p21 ↑ (model-dependent) Cell-cycle inhibition weaker than cancer cells in comparative oral-cell experiments G Cytostasis Phase and molecular mediators vary by tumor type; G2/M arrest is repeatedly reported.
9 EMT invasion and MMP signaling MMP-9 ↓; N-cadherin ↓; EMT ↓; invasion ↓ ↔ G Anti-invasive phenotype Partly downstream of AKT, NF-κB, STAT3, and Hippo signaling.
10 Chemosensitization Chemo sensitivity ↑; STAT3 ↓; FOXM1 ↓; RAD51 ↓; survivin ↓ (combination-dependent) Some normal-tissue chemotherapy toxicity ↓ in animal models G Enhancement of anticancer drug response Reported with paclitaxel, doxorubicin, 5-FU, bortezomib, thalidomide, and experimental combinations; evidence remains preclinical.
11 ERK NRF2 HO-1 antioxidant signaling Context-dependent; potentially cytoprotective ERK ↑; NRF2 ↑; HO-1 ↑; ROS injury ↓ R, G Secondary antioxidant cytoprotection This axis is best established in non-malignant oxidative-stress models and should not be interpreted as a principal anticancer mechanism.
12 Clinical Translation Constraint Effective concentrations frequently ≥50 µM; many studies use 100–300 µM Systemic oral exposure very low G Bioavailability and exposure limitation Absolute oral bioavailability in rats has been reported at approximately 0.45%. Poor solubility, permeability, and intestinal first-pass metabolism substantially separate experimental concentrations from conventional oral exposure.

TSF: P: 0–30 min     R: 30 min–3 hr     G: >3 hr






Morin in Alzheimer’s disease: Morin has substantial preclinical neuroprotective evidence but no established clinical efficacy. Experimental effects include direct or indirect inhibition of GSK-3β and CDK5-associated tau phosphorylation, reduction of amyloidogenic APP processing, increased Aβ degradation, reduction of oxidative and mitochondrial injury, attenuation of pathological mitochondrial Ca²⁺ loading, suppression of neuroinflammation, and preservation of synaptic function. Transgenic mouse experiments have shown reductions in Aβ plaque burden and tau pathology with improved cognitive performance. More recent animal work also implicates NRF2/HO-1/GPX4-mediated antioxidant and anti-ferroptotic signaling.

Morin Alzheimer’s Mechanisms

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 GSK-3β and tau phosphorylation GSK-3β ↓; p-tau ↓ R, G Anti-tau activity Morin inhibits GSK-3β activity and reduces tau hyperphosphorylation in cellular and transgenic mouse models.
2 Amyloidogenic APP processing ADAM10 ↑; BACE1 ↓; PS1 ↓; Aβ production ↓ G Reduced amyloidogenesis Demonstrated in APP/PS1 transgenic mice with decreased cerebral Aβ production and plaque burden.
3 Aβ clearance Aβ-degrading enzymes ↑; Aβ burden ↓ G Enhanced amyloid clearance Complements reduced amyloidogenic APP processing.
4 Mitochondrial ROS and bioenergetics ROS ↓; mitochondrial depolarization ↓; respiratory capacity ↑ P, R Mitochondrial neuroprotection Morin attenuates Aβ oligomer-induced oxidative stress, respiratory dysfunction, cytochrome-c release, and neuronal injury.
5 Mitochondrial calcium dysregulation Mitochondrial Ca²⁺ overload ↓ P, R Prevention of mitochondrial injury Observed in Aβ-exposed neuronal models and linked to preservation of mitochondrial membrane potential.
6 Neuroinflammation NF-κB ↓; TNF-α ↓; IL-1β ↓; IL-6 ↓; glial activation ↓ R, G Anti-inflammatory neuroprotection Supported by Aβ animal models and transgenic AD models.
7 NRF2 HO-1 GPX4 and ferroptosis NRF2 ↑; HO-1 ↑; GPX4 ↑; ferroptotic stress ↓ R, G Antioxidant and anti-ferroptotic protection More recent evidence from chemically induced AD-like rat models; significance in human AD is unknown.
8 Synaptic and cognitive function Synaptic markers ↑; BDNF ↑ (model-dependent); memory performance ↑ G Functional neuroprotection Observed in animal studies; no corresponding clinical efficacy data are available.
9 Clinical Translation Constraint Human efficacy unestablished; oral bioavailability very low G Translation limitation Promising mechanistic animal evidence is offset by poor pharmacokinetics and absence of demonstrated therapeutic efficacy in people with Alzheimer’s disease.

TSF: P: 0–30 min     R: 30 min–3 hr     G: >3 hr



Scientific Papers found: Click to Expand⟱
8880- MOR,    Morin, a Natural Flavonoid, Activates the PINK1/Parkin Pathway to Induce Mitophagy, Promote Apoptosis, and Suppress Cancer Stemness in Pancreatic Cancer
- in-vitro, PC, NA
tumCV↓, TumCMig↓, TumCI↓, CSCs↓, N-cadherin↓, Snail↓, Zeb1↓, SOX2↓, Nanog↓, OCT4↓, E-cadherin↑, ALDH↓, mtDam↑, MMP↓, compV↓, mt-ROS↑, PINK1↑, PARK2↑, AMPK↑, LC3A↑, LC3B↑, MFN2↓, MitoP↑, Apoptosis↑, Casp3↑, Casp9↑, Cyt‑c↑,
8881- MOR,    Molecular Docking, Dynamics, and Preclinical Studies Reveal Morin Hydrate as a Potent PPARγ and Nrf2 Agonist That Mitigates Colon Inflammation
- vitro+vivo, IBD, NA
*colonLen↑, *MPO↓, *Inflam↓, *NRF2↑, *PPARγ↑,

Showing Research Papers: 51 to 52 of 52
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 52

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   Catalase↑, 1,   GSH↓, 1,   GSH↑, 1,   MDA↓, 1,   ROS↓, 1,   ROS↑, 6,   ROS↝, 1,   mt-ROS↑, 2,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↑, 1,   p‑CDC2↓, 1,   CDC25↓, 1,   compV↓, 1,   MFN2↓, 1,   mtDam↑, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACADS/SCAD↓, 1,   AMP↑, 1,   AMPK↓, 1,   AMPK↑, 1,   p‑AMPK↑, 2,   ATP↓, 1,   GlucoseCon↓, 1,   p‑GSK‐3β↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

APAF1↑, 1,   Apoptosis↑, 11,   BAD↑, 2,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 6,   Bcl-xL↓, 6,   BID↑, 1,   Casp10↑, 1,   Casp3↑, 7,   cl‑Casp3↑, 2,   Casp8↑, 2,   cl‑Casp8↑, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 3,   Diablo↑, 1,   DR5↑, 2,   FADD↑, 2,   Fas↑, 1,   FasL↑, 2,   IAP1↓, 2,   IAP2/BIRC3↓, 1,   Mcl-1↓, 2,   PUMA↑, 1,   survivin↓, 3,   TumCD↑, 1,   XIAP↓, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 8,   Akt↑, 1,   p‑Akt↓, 5,   p‑EGFR↓, 1,   p‑ERK↓, 1,   p‑ERK↑, 1,   Hippo↑, 1,   IκB↓, 1,   JAK1↓, 1,   JAK2↓, 1,   p‑JNK↓, 1,   MAPK↓, 1,   Mst1↑, 1,   mTOR↓, 1,   mTOR↑, 1,   p‑mTOR↓, 2,   p70S6↑, 1,   PI3K↓, 2,   PI3K↑, 1,   PIAS-3↑, 1,   SHP1↑, 1,   Sp1/3/4↓, 2,   Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   p‑STK11/LKB1↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

FOXM1↓, 1,   GATA3↑, 1,   miR-155↓, 1,   OCT4↓, 1,   SOX2↓, 1,   tumCV↓, 7,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6?, 1,   Beclin-1/ATG6↑, 1,   LC3A↑, 2,   LC3B↑, 2,   MitoP↑, 1,   PARK2↑, 1,   TumAuto↑, 1,   p‑ULK1/ATG1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   DNArepair↓, 1,   P53↑, 1,   PARP↓, 2,   PARP↑, 1,   cl‑PARP↑, 2,   PARP1↓, 1,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   Chk2↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 2,   GADD45A↑, 1,   P21↑, 4,   TumCCA↑, 6,   WEE1↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   cFos↓, 1,   CSCs↓, 1,   Nanog↓, 1,   TumCG↓, 1,   TumCP↓, 6,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,   E-cadherin↑, 1,   EMT↓, 4,   Fibronectin↓, 1,   KRAS↓, 1,   MMP2↓, 2,   MMP9↓, 7,   N-cadherin↓, 4,   Snail↓, 1,   TumCA↓, 1,   TumCI↓, 5,   TumCMig↓, 4,   uPA↓, 1,   uPAR↓, 1,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VCAM-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 1,   GLUT1↓, 1,   MMP?, 1,   MMP↓, 6,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   Gal-3↓, 2,   HMGB1↓, 2,   IL18↓, 1,   IL1β↓, 1,   IL6↓, 3,   NF-kB↓, 6,   NLRP3↓, 1,   PGE2↓, 2,   TNF-α↓, 2,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 3,   ChemoSen↑, 12,   Dose↝, 8,   Half-Life↝, 1,   MRP1/ABCC1↝, 1,   selectivity↑, 3,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

p‑EGFR↓, 1,   FOXM1↓, 1,   IL6↓, 3,   KRAS↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↓, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,   RenoP↑, 1,   TumVol↓, 1,  
Total Targets: 178

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 6,   ARE↓, 1,   Bil↓, 1,   Catalase↑, 2,   GPx↑, 3,   GPx4↑, 1,   GSH↑, 2,   HO-1?, 1,   HO-1↑, 5,   Iron↓, 1,   Keap1↓, 1,   MDA↓, 4,   MPO↓, 1,   NRF2↑, 8,   ROS↓, 10,   SOD↑, 4,   TAC↑, 3,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↑, 1,   compIII↑, 1,   compV↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   GSK‐3β↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 2,   BAX↓, 1,   Bcl-2↑, 2,   Casp3↓, 2,   Casp8↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   Ferroptosis↓, 2,   iNOS↓, 1,   p38↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↓, 1,   ERK↓, 2,   ERK↑, 1,   p‑ERK↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↑, 5,  

DNA Damage & Repair(tgid=10) ⓘ

PARP1↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK5↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Wnt↑, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 2,   VCAM-1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 1,   MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 2,   IL6↓, 3,   Inflam↓, 9,   NeuroI↓, 2,   NF-kB↓, 5,   NLRP3↓, 1,   TLR4↓, 2,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   ADAM10↑, 1,   BDNF↑, 3,   PSD95↑, 1,  

Protein Aggregation(tgid=19) ⓘ

APP↓, 1,   APP↝, 1,   Aβ↓, 3,   BACE/β-secretase↓, 2,   PSEN1/PS1↓, 1,   p‑tau↓, 3,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

NR1H4↑, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 5,   BioAv↝, 7,   Dose?, 2,   Dose↝, 7,   eff↑, 1,   Half-Life↓, 1,   Half-Life↑, 1,   P-gp/ABCB1↓, 1,   selectivity↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   ALP↓, 1,   AST↓, 1,   Bil↓, 1,   colonLen↑, 1,   creat↓, 1,   creat↑, 1,   IL6↓, 3,   Urea↓, 1,   Urea↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoP↑, 3,   cognitive↑, 1,   hepatoP↑, 1,   Learn↑, 2,   memory↑, 5,   neuroP?, 1,   neuroP↑, 5,   RenoP↑, 2,   toxicity↓, 1,   toxicity↝, 1,  
Total Targets: 99

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:460  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page